Practice variation in re-resection for recurrent glioblastoma: A nationwide survey among Dutch neuro-oncology specialists.

IF 2.4 Q2 CLINICAL NEUROLOGY Neuro-oncology practice Pub Date : 2023-03-14 eCollection Date: 2023-08-01 DOI:10.1093/nop/npad016
Mark P van Opijnen, Filip Y F de Vos, Rob J A Nabuurs, Tom J Snijders, Rishi D S Nandoe Tewarie, Walter Taal, Joost J C Verhoeff, Jacobus J M van der Hoeven, Marike L D Broekman
{"title":"Practice variation in re-resection for recurrent glioblastoma: A nationwide survey among Dutch neuro-oncology specialists.","authors":"Mark P van Opijnen, Filip Y F de Vos, Rob J A Nabuurs, Tom J Snijders, Rishi D S Nandoe Tewarie, Walter Taal, Joost J C Verhoeff, Jacobus J M van der Hoeven, Marike L D Broekman","doi":"10.1093/nop/npad016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite current best treatment options, a glioblastoma almost inevitably recurs after primary treatment. However, in the absence of clear evidence, current guidelines on recurrent glioblastoma are not well-defined. Re-resection is one of the possible treatment modalities, though it can be challenging to identify those patients who will benefit. Therefore, treatment decisions are made based on multidisciplinary discussions. This study aimed to investigate the current practice variation between neuro-oncology specialists.</p><p><strong>Methods: </strong>In this nationwide study among Dutch neuro-oncology specialists, we surveyed possible practice variation. Via an online survey, 4 anonymized recurrent glioblastoma cases were presented to neurosurgeons, neuro-oncologists, medical oncologists, and radiation oncologists in The Netherlands using a standardized questionnaire on whether and why they would recommend a re-resection or not. The results were used to provide a qualitative analysis of the current practice in The Netherlands.</p><p><strong>Results: </strong>The survey was filled out by 56 respondents, of which 15 (27%) were neurosurgeons, 26 (46%) neuro-oncologists, 2 (4%) medical oncologists, and 13 (23%) radiation oncologists. In 2 of the 4 cases, there appeared to be clinical equipoise. Overall, neurosurgeons tended to recommend re-resection more frequently compared to the other specialists. Neurosurgeons and radiation oncologists showed opposite recommendations in 2 cases.</p><p><strong>Conclusions: </strong>This study showed that re-resection of recurrent glioblastoma is subject to practice variation both between and within neuro-oncology specialties. In the absence of unambiguous guidelines, we observed a relationship between preferred practice and specialty. Reduction of this practice variation is important; to achieve this, adequate prospective studies are essential.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 4","pages":"360-369"},"PeriodicalIF":2.4000,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346413/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npad016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Despite current best treatment options, a glioblastoma almost inevitably recurs after primary treatment. However, in the absence of clear evidence, current guidelines on recurrent glioblastoma are not well-defined. Re-resection is one of the possible treatment modalities, though it can be challenging to identify those patients who will benefit. Therefore, treatment decisions are made based on multidisciplinary discussions. This study aimed to investigate the current practice variation between neuro-oncology specialists.

Methods: In this nationwide study among Dutch neuro-oncology specialists, we surveyed possible practice variation. Via an online survey, 4 anonymized recurrent glioblastoma cases were presented to neurosurgeons, neuro-oncologists, medical oncologists, and radiation oncologists in The Netherlands using a standardized questionnaire on whether and why they would recommend a re-resection or not. The results were used to provide a qualitative analysis of the current practice in The Netherlands.

Results: The survey was filled out by 56 respondents, of which 15 (27%) were neurosurgeons, 26 (46%) neuro-oncologists, 2 (4%) medical oncologists, and 13 (23%) radiation oncologists. In 2 of the 4 cases, there appeared to be clinical equipoise. Overall, neurosurgeons tended to recommend re-resection more frequently compared to the other specialists. Neurosurgeons and radiation oncologists showed opposite recommendations in 2 cases.

Conclusions: This study showed that re-resection of recurrent glioblastoma is subject to practice variation both between and within neuro-oncology specialties. In the absence of unambiguous guidelines, we observed a relationship between preferred practice and specialty. Reduction of this practice variation is important; to achieve this, adequate prospective studies are essential.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
复发性胶质母细胞瘤再切除的实践差异:荷兰神经肿瘤学专家的全国性调查。
背景:尽管目前有最佳治疗方案,但胶质母细胞瘤在初治后几乎不可避免地会复发。然而,由于缺乏明确的证据,目前关于复发性胶质母细胞瘤的指导方针并不明确。再次切除是可能的治疗方式之一,但要确定哪些患者将从中获益却具有挑战性。因此,治疗决定是在多学科讨论的基础上做出的。本研究旨在调查目前神经肿瘤学专家之间的实践差异:在这项针对荷兰神经肿瘤学专家的全国性研究中,我们调查了可能存在的实践差异。通过在线调查,我们向荷兰的神经外科医生、神经肿瘤学家、肿瘤内科医生和放射肿瘤学家提交了 4 个匿名的复发性胶质母细胞瘤病例,并使用标准化问卷调查他们是否建议再次切除以及为什么建议再次切除。调查结果用于对荷兰目前的做法进行定性分析:56名受访者填写了调查问卷,其中15人(27%)为神经外科医生,26人(46%)为神经肿瘤学家,2人(4%)为肿瘤内科医生,13人(23%)为放射肿瘤学家。在 4 个病例中的 2 个病例中,似乎存在临床平衡。总体而言,与其他专家相比,神经外科医生更倾向于建议再次切除。在 2 个病例中,神经外科医生和放射肿瘤专家的建议截然相反:这项研究表明,复发性胶质母细胞瘤的再切除在神经肿瘤专科之间和专科内部都存在实践差异。在缺乏明确指南的情况下,我们观察到了首选做法与专科之间的关系。减少这种实践差异非常重要;要实现这一目标,必须进行充分的前瞻性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Neuro-oncology practice
Neuro-oncology practice CLINICAL NEUROLOGY-
CiteScore
5.30
自引率
11.10%
发文量
92
期刊介绍: Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving
期刊最新文献
Foreword. Role of the tumor board when prescribing mutant isocitrate dehydrogenase inhibitors to patients with isocitrate dehydrogenase-mutant glioma. Financial challenges of being on long-term, high-cost medications. How do I prescribe and manage mIDH inhibitors in patients with IDH-mutant glioma? Vorasidenib: Patient and caregiver information sheet.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1